Copyright
©The Author(s) 2024.
World J Orthop. Sep 18, 2024; 15(9): 870-881
Published online Sep 18, 2024. doi: 10.5312/wjo.v15.i9.870
Published online Sep 18, 2024. doi: 10.5312/wjo.v15.i9.870
Table 1 Risk of bias assessment
Manuscript type | Ref. | Related questions | Total | Risk of bias | ||||||||||||
Randomized control trial | Was true randomization used for assignment of participants to treatment groups? | Was allocation to treatment groups concealed? | Were treatment groups similar at the baseline? | Were participants blind to treatment assignment? | Were those delivering the treatment blind to treatment assignment? | Were treatment groups treated identically other than the intervention of interest? | Were outcome assessors blind to treatment assignment? | Were outcomes measured in the same way for treatment groups? | Were outcomes measured in a reliable way? | Was follow-up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? | Were participants analyzed in the groups to which they were randomized? | Was appropriate statistical analysis used? | Was the trial design appropriate and any deviations from the standard randomized control trial design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial? | |||
Godek et al[13] | Y | Y | Y | Y | N | Y | N | Y | Y | Y | Y | Y | Y | 85% | Low | |
Cohort studies | Were the two groups similar and recruited from the same population? | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | Was the exposure measured in a valid and reliable way? | Were confounding factors identified? | Were strategies to deal with confounding factors stated? | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | Were the outcomes measured in a valid and reliable way? | Was the follow-up time reported and sufficient to be long enough for outcomes to occur? | Was follow-up complete, and if not, were the reasons for loss to follow-up described and explored? | Were strategies to address incomplete follow-up utilized? | Was appropriate statistical analysis used? | N/A | N/A | |||
Becker et al[15] | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | N/A | N/A | 100% | Low | |
Goni et al[16] | Y | Y | Y | N | N | Y | Y | Y | Y | Y | N | N/A | N/A | 73% | Low | |
HS et al[17] | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | N/A | N/A | 100% | Low | |
Godek et al[19] | Y | Y | Y | N | N | Y | Y | Y | Y | Y | Y | N/A | N/A | 82% | Low | |
Godek et al[18] | Y | Y | Y | N | N | N | Y | Y | Y | Y | Y | N/A | N/A | 73% | Low |
- Citation: Rajkovic CJ, Merckling ML, Lee AW, Subah G, Malhotra A, Thomas ZD, Zeller SL, Wainwright JV, Kinon MD. Conservative management of spinal pathology with autologous conditioned serum: A systematic review of the literature. World J Orthop 2024; 15(9): 870-881
- URL: https://www.wjgnet.com/2218-5836/full/v15/i9/870.htm
- DOI: https://dx.doi.org/10.5312/wjo.v15.i9.870